-
Glutamine demonstrated as clinical standard now for inclusion into cancer treatment:
“Preclinical data demonstrated glutamine supplementation, not deprivation, elicited antitumor effects”
“Recently, several groups have shown glutamine supplementation to elicit antitumor effects in vivo while achieving elevated glutamine concentrations in the blood and intratumorally to generate tumor response, compared to controls. For example, melanoma-bearing mouse models treated with oral glutamine exhibited significant reductions in tumor volume with corresponding increases in serum glutamine concentrations, compared to mice fed with control diets [12]. In vivo PDAC mouse models have corroborated the antitumor effects of supplementing oral glutamine at 5 mg/kg per day doses of 100% glutamine, compared to controls, where mice treated with glutamine supplementation demonstrated significantly prolonged survival compared to the control [13].”
The other two look to be a flush niacin derivative/analogue (so because it was altered, thus toxic and pretty much worthless) and an NAMPT-inhibitor (essentially an advanced kinda chemotherapy).
This is a huge step forward though for it finally to be accepted by the most prestigious cancer institution the truth of glutamine’s important roll in the etiology and pathology, and intervene with it properly here by at least including it into treatment finally.
Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
https://www.mdpi.com/2227-9059/11/5/1392
mdpi.com
Advanced pancreatic cancer is underscored by progressive therapeutic resistance and a dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation, not deprivation, elicited antitumor effects against pancreatic ductal adenocarcinoma (PDAC) alone and in combination with gemcitabine in a … Continue reading
